Abivax receives DSMB recommendation to continue ongoing extension study of its completed phase 2a clinical trial in ulcerative colitis patients
Favorable safety and statistically significant efficacy demonstrated in a completed randomized, double-blind, placebo-controlled induction clinical trial based on clinical and endoscopic endpoints
One-year open-label extension study ongoing, with patients already well treated with ABX464 for a total of 5 to 12 months (induction and maintenance study)
Protocol for phase 2b clinical trial in 250 patients to be submitted in
ABX464-101 was conducted with 32 patients for induction treatment of moderate-to-severe ulcerative colitis (UC), refractory to anti-TNF monoclonal antibodies or corticosteroids. The final data from this 2-month double-blind clinical study indicated that ABX464 was safe, well-tolerated, and demonstrated statistically significant efficacy based on both clinical and endoscopic endpoints in this study. The difference between ABX464 and placebo in colorectal mucosal healing was statistically significant (p<0.03). Furthermore, the onset of the therapeutic effect of ABX464 was rapid, with a difference of the reduction of the partial Mayo score1 between ABX464 and placebo being observed at the first assessment following treatment for two weeks, which became significant (p<0.02) at eight weeks (likelihood ratio CHI-square test). Similarly, the difference of the reduction of the total Mayo score2 after eight weeks was statistically significant (p<0.03)3.
Based on the long-term results of ABX464 (5 to 12 months of treatment already completed in induction and/or maintenance studies), the study’s Data Safety and Monitoring Board recommended continuation of the maintenance study and, in addition, granted a positive opinion regarding a second extension for an additional 12 months, making ABX464-102 into a 24-month extension study. The protocol amendment is being submitted to regulatory authorities this week.
“We are very pleased, as the extension of the ABX464-102 maintenance study from 12 to 24 months was proposed by the investigators based on medical benefit and was initially requested by trial patients, suffering from this chronic disease, who wanted to ensure continued access to ABX464 treatment,” said Jean-Marc Steens, M.D., Chief Medical Officer of
“I strongly support the recommendation of the Data Safety Monitoring Board to not only continue the current one year maintenance study, but also to extend the study for a second year, which we expect can be very beneficial for the patients currently receiving ABX464,” said Prof.
At the end of the completed 2-month induction treatment study, 22 Patients (15 previously treated with ABX464 and 7 on placebo) were transferred to the 12 months open-label maintenance study with ABX464. As of today, 20/22 patients have completed at least 5 months of treatment in the maintenance study, with one patient being treated with ABX464 for more than one year.
“The favorable safety and medical benefit observed in this study further strengthen our commitment to bring ABX464 to the many patients with ulcerative colitis and other inflammatory diseases, like Crohn’s disease and rheumatoid arthritis, who are not adequately helped by current therapies,” saidProf. Dr.
The full clinical trial data of the completed induction study and interim data of the maintenance study will be presented at upcoming international scientific conferences, as well as submitted for publication in a leading medical journal.
About Ulcerative Colitis
Ulcerative colitis is a debilitating inflammatory bowel disease in adults and children, with limited therapeutic management options for many patients. It is estimated that close to 1 million patients with ulcerative colitis live in
About ABX464
Inflammation is a cornerstone of inflammatory bowel disease (IBD), more specifically in ulcerative colitis and Crohn’s disease. When evaluated in a mouse model of IBD, ABX464 demonstrated a long-lasting effect in preventing the typical symptoms of inflammatory colitis, including histological improvements5. A ten-fold increase of miR124, a micro-RNA with potent anti-inflammatory properties in peripheral blood mononuclear cells (PBMCs) was observed. ABX464 was shown to target the cap binding complex (CBC), which is a novel mechanism of action for anti-inflammatory drugs. By ABX464 binding to the CBC, it reinforces the biological functions of this complex in cellular RNA biogenesis including splicing. Therefore, the molecule acts inside injured immune cells to preserve the integrity of newly synthesized RNA. ABX464 enhanced the expression and splicing of a single long non-coding RNA to generate the anti-inflammatory miR-124. This work was conducted by the cooperative laboratory between
About
DISCLAIMER
This press release contains forward-looking statements, forecasts and estimates with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document de Référence). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in
| ______________ |
|
1 The partial Mayo Score is composed of stool frequency, rectal bleedings and the physician’s global assessment of disease severity. 2 The total Mayo score is composed of the 3 parameters listed above, plus mucosal appearance at endoscopy 4 Company estimate based on Global Data 5 K Chebli et al., The Anti-HIV Candidate ABX464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages. Nature Scientific Reports 2017, DOI:10.1038/s41598-017-04071-3 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20181205005926/en/
Source:
Abivax
Didier Blondel
Chief Financial Officer
didier.blondel@abivax.com
+33 1 53 83 08 41
Media (EU)
ALIZE RP
Aurore Gangloff / Caroline Carmagnol
abivax@alizerp.com
+33 1 44 54 36 66
Media (US)
LifeSci Public Relations
Mike Tattory
Mtattory@lifescipublicrelations.com
+1 (646) 571-4362
Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254